Merck MSD gives birth to women’s health specialist, Organon

It’s D-Day. The pharmaceutical giant Merck MSD is now separating itself from several billion euros of activity, under the Organon banner, named after the Dutch laboratory acquired in 2007 by Schering Plow, itself acquired by Merck MSD in 2009.

Organon, which will debut on the stock market, if it remains specializing in women’s health, receives additional assets as a birth gift: a small biosimilars business of 300 million dollars set to grow and a portfolio of a Fifty mature Merck MSD products with a turnover of 4.5 billion. The new entity that is entering the New York Stock Exchange thus posted some 6.5 billion dollars in turnover at the end of 2020.

–